Related Experiment Video
Updated: Aug 13, 2025
11:47
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
10.7K
Alpha-Pinene Alleviates Motor Activity in Animal Model of Huntington's Disease via Enhancing Antioxidant Capacity
Helia Rahmani1,2, Mohammad Raman Moloudi3, Paria Hashemi4
1Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Neurochemical Research
|January 23, 2023
Summary
Alpha-pinene, a natural antioxidant, shows promise in treating Huntington's disease (HD). This study found alpha-pinene improved motor function and reduced oxidative stress in an HD animal model, suggesting its therapeutic potential.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Huntington's disease (HD) is a progressive, inherited neurodegenerative disorder.
- Antioxidants show potential in slowing HD progression, with ongoing clinical trials.
- Alpha-pinene, a monoterpene, possesses known antioxidant properties.
Purpose of the Study:
- To investigate the neuroprotective effects of alpha-pinene in an animal model of Huntington's disease.
- To evaluate alpha-pinene's impact on motor function and biochemical markers of oxidative stress in HD.
Main Methods:
- An animal model of Huntington's disease was established using 3-Nitropropionic acid (3-NP) in Wistar rats.
- Rats were divided into groups receiving 3-NP or alpha-pinene plus 3-NP.
- Evaluations included motor skill tests (rotarod, narrow beam, locomotor activity) and biochemical analysis of oxidant/antioxidant markers in the cortex and striatum.
Main Results:
- Alpha-pinene significantly improved body weight, rotarod performance, narrow beam traversal time, and locomotor activity in 3-NP treated rats.
- Biochemical assays showed alpha-pinene reduced elevated levels of oxidant markers (nitrite, malondialdehyde) in the cortex and striatum.
- Alpha-pinene normalized decreased levels of antioxidant enzymes (superoxide dismutase, catalase, glutathione) in both brain regions.
Conclusions:
- Alpha-pinene effectively prevented motor dysfunction in a 3-NP-induced Huntington's disease animal model.
- The findings suggest that alpha-pinene's protective effects are mediated by restoring the oxidant-antioxidant balance.
- Alpha-pinene demonstrates potential as a therapeutic agent for Huntington's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
330
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
330
01:22Alzheimer's Disease: Treatment
237
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237
01:15Parkinson's Disease: Overview
641
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
641